跳至主要内容

Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA

 Recently, Gluetacs Therapeutics (Gluetacs)'s first class 1 new drug, GT919 Capsules, a molecular glue degradation agent pipeline, was approved by the US Food and Drug Administration (FDA) to enter clinical trials.  It is for the treatment of malignant hematological tumors.


The pipeline was previously approved by the National Medical Products Administration (NMPA) for clinical trials on December 20, 2022, and is currently undergoing Phase I clinical trials in China.  This is the first product pipeline of Gluetacs that has been approved for clinical trials in both China and the United States, and it is another milestone in the globalization process of Gluetacs.  For the research and development of GT919, Shanghai Medicilon Inc, (Medicilon) relied on its solid R&D strength to efficiently complete the drug discovery to clinical application for GT919, including drug discovery, pharmaceutical research, and preclinical research based on Medicilon's one-stop preclinical research services platform.  This has been highly recognized by Gluetacs.

Medicilon's One-Stop Preclinical R&D Service Platform
Empowering new drug research and development with faster and more economical


The approval of new drugs is inseparable from the full collaboration of both parties.  With the mutual trust and support of Medicilon and Gluetacs, Medicilon provided one-stop preclinical R&D services for GT919, helping to obtain clinical approval, which demonstrated the R&D innovation strength of innovative pharmaceutical companies.  It also once again reflects the capabilities and advantages of Medicilon's one-stop biopharmaceutical preclinical R&D service platform.

Relying on the technological advantages and R&D platform advantages accumulated over the past 19 years, Medicilon has continuously expanded the upstream and downstream areas of the industrial chain around the needs of new drug R&D, and successfully created a comprehensive and integrated preclinical CRO service model.  Not only can the research and development links be seamlessly connected in series, but also can be integrated into a parallel research and development model.  Therefore, Medicilon presents the service advantages of strict planning, efficient coordination, and orderly advancement, which can empower new drug research and development in faster, better, and less costly ways.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文